Volitionrx Stock Price, News & Analysis

Volition (NYSE: VNRX) announced a preprint describing Capture-Seq™, a method that physically enriches ultrashort transcription factor–bound cfDNA for liquid biopsy. The company reports a 180-fold (18,000%) enrichment, removal of ~99% background DNA, and two patent-pending separation technologies. In a small training cohort of 70 subjects (49 cancer patients), analysis reportedly achieved 100% sensitivity and 100% specificity. Volition projects a $23 billion annual TAM and is seeking commercial partners; results require independent validation in larger studies.

Volition (NYSE AMERICAN: VNRX) presented two abstracts at the North America Conference on Lung Cancer in Chicago reporting clinical data for its Nu.Q® Cancer assays. The studies found that circulating H3K27Me3-nucleosome levels rise with disease stage and that baseline levels at diagnosis act as an independent prognostic biomarker for overall survival, including in ctDNA-negative patients.

One poster described pre-operative H3K27Me3 measurements that stratify non-small cell lung cancer patients by recurrence-free and overall survival and may flag micro-metastatic disease to guide systemic-therapy decisions. The reports note an initial hospital order to complete internal certification ahead of clinical use, and Volition said it is progressing toward first clinical deployment of Nu.Q® Cancer.

Volition (NYSE AMERICAN: VNRX) announced that its Nu.Q® NETs H3.1 assay has been included as the sole biomarker in DETECSEPS, a French real-world program for early detection of sepsis funded under France 2030.

The DETECSEPS consortium received approximately €6.3 million (~$7.3 million) in government financing. Results cited show H3.1 accurately distinguishes sepsis from non-infectious inflammation, correlates with disease severity, and outperforms APACHE II and SOFA for ICU admission prognostic power. H3.1 can be run on the IDS i10® analyzer with results within one hour. The release highlights a potential national rollout and cites ~166 million annual sepsis cases as a large testing opportunity.

VolitionRx (NYSE AMERICAN: VNRX) announced the first commercial sale of its Nu.Q® Cancer assays to Hospices Civils de Lyon in Lyon, France on November 25, 2025.

The order is to complete internal clinical certification ahead of introducing Nu.Q® into routine clinical practice for cancer management, with cited evidence that methylated nucleosome biomarkers at non‑small cell lung cancer (NSCLC) diagnosis correlate with survival and progression‑free survival and can help identify patients who may benefit from curative care.

Company executives described the sale as a commercialization milestone and a step toward clinical use and licensing of Nu.Q® in human cancer.

VolitionRx (NYSE AMERICAN: VNRX) reported third quarter 2025 results and a business update on November 13, 2025, and will host an earnings call on November 14, 2025 at 8:30 a.m. ET.

Key financials: Q3 revenue was $0.6 million (+32% YoY). Operating expenses were down 10% year‑over‑year for the quarter and 18% for the first nine months. Net loss decreased 8% for Q3 and 20% year‑to‑date. Net cash used in operations was $3.6 million in the quarter, down 33% YoY. Post‑quarter, the company received approximately $6.1 million net proceeds from a public offering.

Management highlighted new human agreements with Werfen (APS) and a co‑marketing/services deal with Hologic, ongoing discussions with ~10 diagnostics/liquid‑biopsy firms, and forthcoming peer‑reviewed publications including Capture‑Seq™ developments.

VolitionRx (NYSE AMERICAN: VNRX) will host its Third Quarter 2025 earnings and business update conference call on Friday, November 14, 2025 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time).

The call will be hosted by Louise Batchelor, Group Chief Marketing & Communications Officer, with Cameron Reynolds, President and Group CEO; Terig Hughes, Group CFO; and Dr. Jake Micallef, Chief Scientific Officer, discussing Q3 2025 financial and operating results and upcoming milestones.

Dial-in numbers, Conference ID 13757129, a live audio webcast link, and a telephone replay available through November 28, 2025 are provided for investors and analysts.

Volition (NYSE AMERICAN: VNRX) donated its Nu.Q® Vet Cancer Test to HOPE Animal-Assisted Crisis Response Dogs at the organization's annual conference in Virginia Beach on Oct. 17, 2025.

The donation provided screening for crisis-response canines—prioritizing earlier cancer detection for older dogs and high-risk breeds—while Volition and partners handled sample collection and processing. The company also promoted a free DVM360 webinar featuring veterinary oncologist Dr Sue Ettinger on clinical evidence, sample processing, result interpretation, and practice integration.

VolitionRx (NYSE AMERICAN: VNRX) priced an underwritten public offering on Oct 10, 2025 of 11,550,000 common shares with warrants to purchase up to 11,550,000 shares at a public offering price of $0.52 per share-plus-warrant (with $0.01 allocated to the warrant). Each warrant is exercisable immediately at $0.60 and expires five years after issuance. Volition granted the underwriter a 30-day option for an additional 1,732,500 shares with accompanying warrants. Expected aggregate gross proceeds before expenses are approximately $6.0 million, with potential additional proceeds of about $6.9 million if warrants are fully exercised. The offering is expected to close on or about Oct 14, 2025, with net proceeds for R&D, clinical studies, commercialization, working capital and potential acquisitions.

VolitionRx (NYSE AMERICAN: VNRX) announced a proposed underwritten public offering of its common stock and accompanying common stock purchase warrants on October 9, 2025. The company said it will grant the underwriter a 30‑day option to buy up to an additional 15% of the shares and warrants at the public offering price, subject to underwriting discounts and commissions.

Volition intends to use net proceeds for research and product development, clinical studies, commercialization, working capital and potential strategic acquisitions. Newbridge Securities Corporation is sole book‑running manager. The offering is being made from a Form S‑3 shelf registration declared effective on April 18, 2025, and final terms depend on market conditions.